Day 2 of the #EANO2026 scientific programme is underway in Rome! Another full day of high-level science, clinical advances & exchange across all disciplines in #NeuroOncology awaits.
📍Don’t miss today’s highlights, presented in comments:
Full programme:
www.eano.eu/eano2026/pro...
#BrainTumor #EANO

#EANO2026 continues in #Rome on another beautiful day ☀️

This morning, don’t miss:
➡️selected abstracts sessions 📄
➡️pro/contra debate on chemo-RT for IDH-mutant grade 3 gliomas, from Susan Short and Martin van den Bent 🧠

Looking forward to another full day of science and discussion!
#radiotherapy

Congratulations to Steven Pollard on receiving the #EANO Research Award 2026 at #EANO2026 in #Rome!
The award recognises his outstanding contributions to #NeuroOncology research, particularly his work advancing our understanding of glioblastoma biology & cancer stem cells. Congratulations, Steven! 👏

👏 Congratulations to Susan Short on receiving the #EANO Diversity and Inclusion Award 2026 at #EANO2026 in #Rome!
This award recognises her long-standing commitment to diversity and inclusion within EANO and the wider #NeuroOncology community. Thank you, Susan, for your outstanding commitment!

We're excited to be in Rome this weekend at #EANO2026! @ucsfhealth.bsky.social neuropsychologist Melissa Brie, PsyD, is presenting her work developing a telehealth-based educational series about integrative health for patients living with a brain tumor.
@eortc.org

Poster session time at #EANO2026! 🧠
If you’re around, don’t miss the #Radiotherapy poster section as well.
Lots of interesting work on RT, from quality assurance, dose, and treatment
#RadiationOncology #NeuroOncology #RTQA #Radiotherapy

👏Raffaella presenting at #EANO2026 today.

The ARGOS post hoc analysis of EORTC-1709-BTG/CCTG CE.8 (MIRAGE) explored the relationship between radiotherapy quality assurance (RTQA), uninvolved-brain dose, survival, and treatment-related toxicity in patients with glioblastoma.

At #EANO2026, #EORTC 2227-LEGATO trial is addressing an important question: does adding #reirradiation to lomustine improve outcomes compared with lomustine alone in #glioblastoma?
Hopefully this phase III trial will generate the evidence needed to define the role of reRT at first progression.

Congratulations to all #EANO2026 award winners, well deserved!
@eanoassociation.bsky.social @mj-mair.bsky.social @maxmastall.bsky.social @galldiks.bsky.social @rdepietro.bsky.social

Congratulations to Michael Weller on receiving the prestigious #EANO Leadership Award 2026 at #EANO2026 in #Rome! This award recognises his outstanding contributions to #NeuroOncology and his long-standing commitment to EANO. Thank you for helping shape EANO and the field of neuro-oncology!

Starting now at #EANO2026: the EANO-EORTC session!
Looking forward to Prof. Weller’s talk on trial design pitfalls, followed by presentations of ongoing #EORTC trials: GLIO-RARE, LEGATO, LUMEN and VIGOR.
A very relevant session on how we design better neuro-oncology trials, not just new treatments.

Highlighting the #EANO2026 Awardees! Congratulations to Isabelle Rydén on receiving the #EANO Nurse & Allied Health Professional Award 2026 at #EANO2026 in #Rome!

👏 International academic collaboration delivering answers.

Just presented at #EANO2026, the ROAM/EORTC-1308 phase III trial found that radiotherapy significantly reduces recurrence risk after complete resection of atypical meningioma.

🔗 www.eortc.org/blog/2026/09...

@eanoassociation.bsky.social

📢 Just presented at #EANO2026 – and now published simultaneously in @thelancet.com! Results from the international multicentre randomised controlled ROAM/EORTC1308 trial, addressing radiotherapy vs. observation following surgical resection of atypical meningioma. 👉
www.thelancet.com/journals/lan...

ROAM in Rome at #EANO2026 !

Results from the EORTC 1308/ROAM trial: in resected WHO grade 2 #meningioma, adjuvant #radiotherapy improved 5-year DFS compared with observation (79.9% vs 62.3%; HR 0.51).
Important evidence for a long-debated question!

@eanoassociation.bsky.social @eortc.org

Welcome to #EANO2026! It’s official – Europe’s largest neuro-oncology congress is underway in Rome!
We are delighted to have the global #NeuroOncology community with us and look forward to three inspiring days of scientific exchange, new connections and great conversations. 🇮🇹 #EANO #Rome

#EANO2026 Chair Giuseppe Minniti takes the stage to officially open the congress, kicking off a packed programme with 44 scientific sessions, poster presentations, and contributions from scientific partners such as @eortc.org
#radiotherapy #EANO #EORTC

Let’s get started with the welcoming remarks and presidential address at #EANO2026!
@eanoassociation.bsky.social @mj-mair.bsky.social @maxmastall.bsky.social @galldiks.bsky.social @rdepietro.bsky.social

Huge congrats to Dr. Andreas Hottinger on his oral presentation at #EANO2026!

Dr. Hottinger presented on the #BrainTumor Trial Finder, a tool built by ancora.ai to help patients & providers navigate #clinicaltrials.

For those at @eanoassociation.bsky.social come to the 5P booth to learn more!

The #EANO2026 scientific programme kicks off today! Following yesterday’s Educational Day, we are looking forward to a packed programme of scientific sessions, new insights and exchange across the international #NeuroOncology community.
Explore today’s programme 👉 www.eano.eu/eano2026/pro...